BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Medimetriks Pharmaceuticals, Inc. Begins Operations; Bradley Pharmaceuticals (BDY) Founder and Senior Management Form Company Specializing in Dermatology and Podiatry Markets


5/13/2008 8:27:33 AM

FAIRFIELD, N.J., May 13 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced today that it commenced operations. The newly-formed Company, led by the founder and the key Senior Management Team of the former Bradley Pharmaceuticals (NYSE: BDY - News), will develop, license and commercialize innovative prescription products for the Dermatology and Podiatry marketplaces. The Company is aggressively pursuing licensing opportunities, company and product acquisitions and initiating the development of a series of brands that will fill unmet needs in the marketplace. Medimetriks' objective is to build a robust product portfolio and become a leading Dermatology and Podiatry specialty company.

Bradley Pharmaceuticals was acquired earlier this year by Nycomed for approximately $350MM. Bradley's Doak Dermatologics Division, which represented approximately 80% of Bradley's revenue, was a leading dermatology company and the largest independent pharmaceutical marketer to the podiatry specialty. Bradley Glassman, the former Senior Vice President of Sales and Marketing for Bradley, will serve as President and CEO of Medimetriks Pharmaceuticals, Brent Lenczycki as Chief Financial Officer and Alan Goldstein as Executive Vice President, Business Development. Daniel Glassman, the former President and CEO of Bradley, will serve as Medimetriks' Chairman of the Board.

"We have an experienced management team that was an important part of Bradley's success," stated Daniel Glassman. "We also have added a strong support team that will allow Medimetriks to achieve both short and long term success. Medimetriks' talented staff demonstrates a tremendous ability to execute with discipline and shares a commitment to creating a meaningful Company that will enhance patient care."

Bradley Glassman said, "We will leverage our core expertise of identifying and delivering important and effective brands in the therapeutic markets that we know so well. In building the Bradley business, we developed long-standing relationships with leading physicians in both the Dermatology and Podiatry specialties. We look forward to working with these physicians and building brands that serve the interests of both their practices and their patients."

The Company is located at 363 Route 46 West, Suite 106, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at www.medimetriks.com .

Source: Medimetriks Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES